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no associations between either pre-PCI or post-PC1 levels of CRP or PAPP-A and steno- 
sis at six months (~~-0.15 for all comparisons). 
Conclusion: PCI leads to a significant post-procedural increase in both CRP and PAPP- 
A levels at 48 hours, but this systemic response was not associated with restenosis rates 
at six months. 
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Diabetes is one of the major risk factor for cardiac events following percutaneous coro- 
nary revascularisation (PCR). However, the role of hyperinsulinism is unclear in this clin- 
ical context. Our objective was to determine the predictive value of fasting plasma insulin 
measured immediately before PCR on subsequent cardiac events. Patients who under- 
went primary or rescue PCR for an acute Ml were excluded. A total of 261 consecutive 
patients, including 82 diabetics (31%), had blood sample measurement of fasting insulin, 
glycemia, and hs-CRP immediately before PCR. The primaly endpoint was a composite 
of death, non-fatal Ml and rehospitalisation for unstable angina. The actuarial rate of 
events was 9.6% at 1 year. 
Multivariate analysis was performed including risk factors such as age, gender, diabetes, 
smoking status, family history of CAD, hypertension, hyperlypidemia, unstable angina, 
left ventricular ejection fraction, extent of CAD, hs-CRP, glycemia and fasting insulin. 
Four independent predictors of events were found in this population: hs-CRP (p=O.OOOl), 
diabetes (p=O.O07), fasting insulin (p=O.Ol) and LVEF (~~0.05). The risk associated with 
high insulin levels (insulin>1 lmUI/L) was more apparent in non-diabetic than in diabetic 
patients (see Table). Conclusion: Fasting insulin measured at baseline is an independent 
predictor of cardiac events at 1 year after PCR. Our results suggest that measurement of 
fasting insulin before PCR may help to identify of group of patients at high risk. 
” events (%) p 
non-diabetics, insulin<1 1 mUIlL 155 5.8% 0.01 
non-diabetics, insulm>ll mu/L 24 18.2% 
Diabetics, insulin<11 mUI/L 57 15.8% 0.10 
Diabetics, insulin>llmU/L -25 26.1% 
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Background: The incidence of subacute stent thrombosis (SAT) after sirolimus-eluting 
stent (SES) implantation for complex lesions is currently not known. We analyzed the 
occurrence of SAT in a large series of consecutive patients treated with this new tech- 
nique. 
Methods: Since 16” April 2002, SES implantation has been adopted as the default strat- 
egy for all patients treated with percutaneous intervention at our institution, as part of the 
RESEARCH registry. Patients were included irrespecbve of clinical presentation and 
lesion morphology. SAT was defined as any thrombotic in-stent occlusion occurring after 
the index procedure. 
Results: By tih September 2002, a total of 479 consecutive procedures were performed 
utilizina at least one SES. Mean aoe was 61*11 years. 71% were men. Overall. 229 
(48%) patients presented wth an acute coronary syndrome and 92 (19%) were diabetic. 
Platelet qlvcomotein inhibitors were used in 119 (25%) orocedures. From a total of 1004 
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SES utilized. 708 (71%) were implanted in type 62/C lesions and 100 (10%) had small 
nominal diameter (2.25 mm). Reference diameter was 2.69 * 0.57 mm. Post-procedure 
MLD and diameter stenosis were 2.28kO.54 mm and 14.7+13.2 mm, respectively. To 
date (mean follow-up period 63+38 days; median 60 days), SAT occurred in 2 patients 
(0.4%), one re-admitted with acute myocardial infarction (within 6 hours after the initial 
procedure) and one with rest pain unstable angina (after 11 days). Both were success- 
fully treated with percutaneous re-intervention. 
Conclusions: Utilization of sirolimus-eluting stent implantation as the strategy of choice 
in the “real world’ of interventional cardiology IS associated with a very low incidence of 
subacute stent thrombosis. 
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Background: Recently, there has been a significant evolution in the specific techniques 
of percutaneous coronary intervention (PCI) and adjunctive pharmacologic therapies. To 
assess the impact of these changes, we evaluated the outcomes of contemporary PCI 
performed in a large international trial. 
Method: We analyzed clinical and anQiOgraphiC characteristics, techniques of PCI, and 
30-day and l-year outcomes of 7,787 patients with de nova lesions who underwent suc- 
cessful PCI between April 1999 and July 2000 as a part of the Prevention of Restenosis 
with Tranilast and its Outcomes (PRESTO) trial. 
Results: Mean patient age was 60 yrs and 77% were male. Baseline clinical features 
were: diabetes: 22%, hypercholesterolemia: 47%, hypertension: 57%, prior Ml: 31%, and 
prior CABG: 9%. Angiographic lesion characteristics included: mean diameter stenosis: 
87.5%, mean lesion length: 13.3 mm, calcified lesions: 18%, bifurcation lesions: 10%. 
total occlusions: lo%, ostial lesions: 6%, and lesions with definite or possible thrombus: 
34%. Overall, 81.7% of patients had single-vessel PCI, 16.5% had two-vessel PCI, and 
1.7% had three-vessel PCI. Device use was: stent: 90.3%. plain balloon angioplasty: 
8.8%. rotablator: 2.5%, and laser, DCA, TEC, and angiojet, each < 1%. All pabents 
received aspirin; patients undergoing stent placement were also treated with a thienopy- 
ridine. GP Ilb/llla inhibitors were used in 35% of patients. Cardiac events at 30 days 
Included: Ml: 0.28%. death: 0.19%, CABG: 0.05%. TVR: 0.50% and any event: 1.17%. At 
9 months, event rates were: Ml: 0.77%, death: 0.82%, CABG: 2.7%. TVR: 10.8%. and 
any event: 12.8%. 
Conclusions: In this large multicenter international trial, bare stem usage was higher 
than in all prior reports, and was associated with a very low 30-day and g-month cardiac 
events. These data can serve as a benchmark against which future trials of coated stents 
can bs compared. 
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Background: Previous studies have shown a benefit with acetlycysteine (ACET) in pre- 
venting contrast-induced nephropathy. but studied only patients with chronic, stable renal 
failure undergoing elective procedures. We hypothesized that those same benefits may 
not hold true for patients in a clinical sening with acute renal failure or in the absence of 
hydration as might ocwr in patients requiring urgent cardiac catheterization. 
Methods: We evaluated the records of 146 consecutive patients with baseline renal 
insufficiency (Cr 21.2 mg/dl) that underwent cardiac catheterization or peripheral angiog- 
raphy (C&h). Patients who received hydration and ACET (600 mg po BID for two days 
peri-procedure) were included in the ACET group. Patients who simply were hydrated or 
received no pre-treatment sewed as controls (Con). Patients were excluded if they had 
an intraaortic balloon pump. bypass within 48 hours, hypotension or inadequate labora- 
tory follow-up. We compared the 48.hour change in serum creatinine (Creat) between 
groups and further analyzed the eflect of hydration on the observed outcomes in both 
groups. 
Results: The two groups were similar in age (Con: 7121; ACET: 70tl yrs), co-morbidi- 
ties (DM, CHF, HTN), amount of contrast used (Con: 151+14; ACET: 146214 ml) and 
cases of chronic versus acute renal failure. Baseline Great (Con: 1.99iO.l I; ACET: 
1.85+0.07 mgldl) was not different. Post procedure, the Great increased significantly 
(w.04) in both groups, but less so in the ACET group (Con: 0.35+0.08: ACET: 
0.14+0.04 mgidl, pa.02). When peri-procedure hydration was considered, the increase 
in Creat for the fully hydrated Con group was only O.li’iO.10 mgldl and not different from 
ACET (0.14iO.04 mQ/dl). In Con patients with inadequate peri-procedure hydration, the 
increase in Great was significantly greater (0.54r0.12 mg/dl) compared to ACET 
(0.17r0.10 mg/dl, pg.001). 
Conclusions: In unselected patients with acute and chronic renal insufficiency undergo- 
ing non-elective Cath, there was no benefit to ACET administration beyond hydration 
akYle. 
